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Direct mechanical thrombectomy (dMT) may result in similar outcomes compared to a 
bridging approach with intravenous thrombolysis (IVT+MT) in acute ischaemic stroke. 
Recent randomised controlled trials (RCTs) have varied in their design and non-inferiority 
margin (NIM).
Aim
We sought to meta-analyse accumulated trial data to assess the difference and non-inferiority 
in clinical and procedural outcomes between dMT and bridging therapy.
Summary of review
We conducted a systematic review of electronic databases following the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Random effects 
meta-analyses were conducted for the pooled data. The primary outcome was good functional 
outcome at 90 days (modified Rankin Scale (mRS)≤2). Secondary outcomes included 
excellent functional outcome (mRS≤1), mortality, any intracranial haemorrhage (ICH), 
symptomatic ICH, successful reperfusion (TICI2b) and procedure-related complications. 
Four RCTs comprising 1633 patients (817 dMT, 816 bridging therapy) were included. There 
were no statistical differences for the 90-day good functional outcome (OR=1.02, 95%CI 
0.84-1.25, p=0.54, I2=0%), and the absolute risk difference was 1% (95% CI −4% to 5%). 
The lower 95% CI falls within the strictest NIM of -10% among included RCTs. dMT 
reduced the odds of successful reperfusion (OR=0.76, 95%CI 0.60-0.97, p=0.03, I2=0%) and 
any ICH (OR=0.65, 95%CI 0.49-0.86, p=0.003, I2=38%). There was no difference in the 
remaining secondary outcomes. The risk of bias for all studies was low.
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The combined trial data assessing dMT versus bridging therapy showed no difference in 
improving good functional outcome. The wide non-inferiority thresholds set by individual 
trials are in contrast with the clinical consensus on minimally important differences. 
However, our pooled analysis indicates non-inferiority of dMT with a 4% margin of 
confidence. The application of these findings is limited to patients presenting directly to MT-
capable centres and real-world workflow times may differ against those achieved in a trial 
setting. 
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Mechanical thrombectomy (MT) has become a standard of care for select acute ischaemic 
stroke (AIS) patients presenting with large vessel occlusion (LVO).1,2 In the seminal trials 
comparing MT plus best medical therapy (BMT) versus BMT alone, intravenous 
thrombolysis (IVT) was administered in both arms when indicated.2 
However, the efficacy of IVT in the setting of LVO is limited, with only 10% achieving 
successful reperfusion.3 Additionally, the administration of bridging IVT before MT may 
incur a time penalty, lead to clot fragmentation and distal embolization, and increase the risk 
of symptomatic intracranial haemorrhage (sICH).4–6 On the other hand, on-board IVT may 
lyse residual distal thrombi after MT and alter thrombus properties to facilitate endovascular 
removal7. These opposing factors have led investigators to question whether pre-treatment 
with IVT confers a net benefit. 
Meta-analyses evaluating clinical and procedural outcomes following direct MT (dMT) 
versus a bridging IVT approach (MT+IVT) predominantly included observational and post-
hoc studies and have yielded conflicting results.8–11 Given the inherent selection biases in 
these investigations, the optimal reperfusion strategy remains unclear. Recently conducted 
randomized-controlled trials (RCT) have reported broadly similar outcomes for both 
approaches. The design of these trials varied such that three were powered to assess non-
inferiority using different thresholds. Furthermore, results from two further ongoing multi-
centre RCTs (SWIFT-DIRECT12 and DIRECT SAFE13) are awaited. Hence, we undertook 
this systematic review and sought to meta-analyse consolidated data to test the null 
hypothesis that there is no difference in clinical and procedural outcomes following dMT 
compared to bridging therapy in AIS patients presenting with LVO.  
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Search Strategy, study selection and eligibility criteria
The study was performed according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines. The protocol was published in the International 
Prospective Register of Ongoing Systematic Reviews PROSPERO (CRD42021233092). We 
systematically searched electronic databases up to January 2021, including 
PubMed/MEDLINE, Scopus, and Cochrane/EMBASE. Additionally, we included results 
presented during the International Stroke Conference (ISC) 2021. The following keywords 
were used in combination or individually by using the Boolean operators “OR” and “AND”: 
randomi$ed, stroke, M1, MCA, large vessel occlusion$, isch$emic stroke, mechanical 
thrombectomy, endovascular therapy, direct thrombectomy, direct endovascular, 
thrombolysis, intravenous, tissue plasminogen activator, bridging thrombolysis, bridging 
therapy, alteplase, tenecteplase. The articles were selected in two stages. First, the titles and 
abstracts were screened for relevant studies and duplicates excluded. Second, the full texts 
were downloaded and assessed for eligibility. The reference lists of included publications 
were then hand-searched for additional relevant studies by three assessors with differences 
resolved by consensus (WB, PD, AP). 
Only RCTs evaluating participants undergoing dMT versus bridging therapy with intravenous 
thrombolysis were included. The exclusion criteria included non-randomized controlled 
(retrospective and prospective) trials and pre-and post-intervention studies, observational and 
cohort studies or post-hoc analyses of RCTs, study protocols, review articles and meta-
analyses, and studies that did not discriminate between dMT and bridging therapy.
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Variables recorded, if available, were the name of the first author, year of publication, study 
recruitment period, trial design, allocation type, primary end-point, stroke centre type, non-
inferiority margin (NIM), sample size, onset to randomization time, randomization to 
alteplase time, randomization to groin time, mean age, number of males, presence of co-
morbidities (namely hypertension, atrial fibrillation, diabetes, smoking, dyslipidaemia, prior 
stroke, prior cerebrovascular disease), prior medications (antiplatelets, anticoagulants), stroke 
aetiology (cardioembolic, large artery atherosclerosis, intracranial atherosclerosis, 
unknown/other), clot location (ICA, M1, M2, tandem occlusion), baseline National Institutes 
of Health Stroke Scale (NIHSS), and Alberta stroke program early CT score (ASPECTS),  
successful reperfusion rate (defined as extended or modified thrombolysis in cerebral 
infarction (TICI) scale of 2b or above), procedure related complications excellent functional 
outcome defined as modified Rankin score of 1 or lower (mRS≤1) at 90 days, good 
functional outcome defined as functional independence with a mRS≤2 at 90 days, sICH 
defined as any ICH with an increase of the NIHSS score of 4 or more within 24 hours or 
death, and ICH, and mortality at 90 days. 
Outcome measures
The primary outcome was a good functional outcome (mRS≤2) at 90 days. The secondary 
clinical outcomes were excellent functional outcome (mRS≤1), mortality, sICH and any ICH. 
The secondary procedural outcomes included successful reperfusion (TICI2b) and 
procedure-related complications.
Statistical analysis
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Study characteristics and extracted variables were summarized using standard descriptive 
statistics. Continuous variables were expressed as means and SD, and categorical variables 
were expressed as frequencies or percentages. Meta-analyses of binary outcomes were 
expressed as odds ratio (OR) with a 95%confidence interval (CI) and continuous variables as 
weighted mean difference (MD) with a 95%CI. A random-effects model and the Mantel-
Haenszel method were used. Risk difference (RD) and OR random-effects meta-analysis to 
assess non-inferiority for the primary outcome (mRS ≤2 after 90 days).
Tests of heterogeneity were conducted with the Q statistic distributed as a chi-square variate 
(assumption of homogeneity of effect sizes). The extent of between-study heterogeneity was 
assessed with the I2 statistic. Funnel plot and Egger’s test were used to assess publication bias 
for the primary outcome. Rob-2 tool was used to evaluate and robvis tool to visualize the 
individual risk of bias of each study. P-values were two-tailed with values <0.05 considered 
statistically significant.  
All analyses were implemented using JASP 0.14.1.0 and Review Manager 5.4.1. 
Ethics
No human participant procedure was involved; therefore, informed consent and ethical 
approval were not essential for this study.
Results
Literature search results
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We screened 838 non-duplicate titles and abstracts, from which 39 full-text articles were 
evaluated (Figure 1). Additionally, one study was identified during ISC 2021. Data was 
extracted from four studies. 14–17
Studies Characteristics
We included four RCTs published between 2020-2021 describing 1633 patients (817 direct, 
816 bridging) that underwent MT with or without iv-alteplase due to LVO in acute ischaemic 
stroke. The studies are summarised in Table 1. The detailed baseline characteristics are 
presented in Table 2.
Clinical outcomes
Bridging therapy and dMT were not associated with a difference in the odds of achieving 
good functional outcome (mRS≤2) at 90 days (Fig. 2; 4 studies; OR=1.02, 95%CI 0.84-1.25, 
p=0.64, I2=0%). 14–17. There was also no difference between groups in the excellent clinical 
outcome (mRs≤1) at 90 days (Fig. 3A; 4 studies; OR=1.08, 95%CI 0.86-1.36, p=0.71, 
I2=0%), mortality at 90 days (Fig. 3B; 4 studies; OR=1.06, 95%CI 0.82-1.37, p=0.67, 
I2=0%), or sICH (Fig. 3C; 4 studies; OR=0.82, 95%CI 0.55-1.21, p=0.31, I2=0%).  14–17 The 
presence of any ICH occurred less frequently in the dMT group (27.8%) versus the bridging 
therapy group (36.3%) (Fig. 3D; 4 studies; OR=0.65, 95%CI 0.49-0.86, p=0.003, I2=38%). 
14–17
Procedural Outcomes 
Successful reperfusion (TICI2b) was achieved in significantly fewer participants in the dMT 
group (76.5%) versus the bridging therapy group (80.9%) (Fig. 4A; 4 studies; OR=0.76, 
95%CI 0.60-0.97, p=0.03, I2=0%).14–17 This finding was mainly observed in two studies 
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including M2 occlusions (versus only ICA and M1 occlusions) (Fig. 4A; 2 studies; OR=0.75, 
95%CI 0.57-0.97, p=0.03, I2=0%)14,17 There was no difference between groups in procedure-
related complications (Fig. 4B; 2 studies; OR=0.83, 95%CI 0.49-1.40, p=0.49, I2=56%). 14–17
Risk of bias
All studies had an overall low risk of bias (Figure 5). Visual inspection of funnel plots did not 
reveal major asymmetry in studies that reported the primary outcome, though there are too 
few to reliably comment, and there was no statistical evidence of publication bias (Egger’s 
test; z=0.95, p=0.343). 14–17
Non-inferiority boundaries
The non-inferiority margin (NIM) for a good clinical outcome was 0.8 (OR) in DIRECT-MT 
and MR CLEAN NO-IV, 0.74 (OR) in SKIP, and -10% (RD) in DEVT. 14–17
The RD in random-effects meta-analysis for the good clinical outcome was 1% (95% CI, 
−4% to 5%; p=0.64; I2=0%). The lower 95% CI bound of −4% fell within the lead NIM of 
−10%, which was the strictest NIM among included RCTs. 
The OR in random-effects meta-analysis for the good clinical outcome was 1.02 (95% CI, 
0.84 to 1.25 p=0.83; I2=0%, Figure 2). The lower 95%CI bound of 0.84 fell within the OR-
NIM of 0.8.
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In this first systematic review and meta-analysis of RCTs comparing dMT versus bridging 
therapy, similar rates of good functional outcome (mRS≤2 at 90 days) were observed in both 
groups. Patients treated with dMT had significantly lower odds of successful reperfusion 
(TICI2b) and any ICH. However, there was no between-group statistical difference in the 
rates of excellent functional outcome (mRS≤1), mortality at 90 days, sICH, and procedural-
related complications. 
The absolute RD in the primary outcome of mRS≤2 at 90 days was 1% (95% CI −4% to 5%). 
Three of the included studies were powered to assess non-inferiority. In contrast to 
superiority trials designed to show that one treatment has greater efficacy than another, a non-
inferiority trial is designed to show that a new treatment is not unacceptably worse than the 
current standard therapy. 18 Non-inferiority is claimed if the lower bound of the CI of the 
treatment effect difference does not exceed a pre-specified difference that is considered 
within acceptable boundaries based on statistical and clinical reasoning. Consensus 
recommendations are that the NIM is the smallest value that would be a clinically important 
effect.
Whilst there is no consensus on a non-inferiority meta-analysis methodology, we adopted the 
approach used where standard non-inferiority testing was applied to aggregated meta-
analyzed outcomes. 19 A NIM can be chosen as an absolute RD or OR depending on 
statistical considerations such as event rates. 20,21 
The strictest NIM among the included RCTs was either 10% RD (DEVT) or 0.8 OR 
(DIRECT-MT and MR-CLEAN NO-IV). Their margins may be considered wide given that 
the minimally clinically important difference (MCID) is 1.5% to 5% as determined by stroke 
experts.22 The lower 95% CI bound of −4% in our analysis fell within the NIM of −5%, 
however not within the more stringent NIM  of −1.5%.23 
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There is an ongoing debate on the use of IVT before MT, proponents of which feel may 
favourably alter clot properties to facilitate removal, lyse distal thrombi and theoretically lead 
to higher first-pass effect rates and successful reperfusion. 24 However, it may also lead to 
clot fragmentation and render a patient ineligible for MT due to distal migration. On the other 
hand, dMT may allow faster door-to-groin-puncture times. However, none of the included 
trials showed a statistically or clinically significant reduction in the door-to-groin puncture 
time in the dMT group. The absence of IVT also potentially reduces the risk of peri-
procedural haemorrhagic complications. Furthermore, there are direct and indirect cost 
implications of administering IVT, which requires a stroke physician’s attendance and drug 
costs, thus favouring dMT as a first-line strategy. 
Overall, our results suggest that IVT facilitates successful reperfusion (TICI2b), however, 
this does not translate to a significant difference in the good clinical outcome (mRS≤2 at 90 
days). The limited efficacy of IVT before MT may be due to the relatively short duration of 
time from IVT administration to groin puncture that may have precluded the full therapeutic 
effect of IVT before the commencement of MT. Although not clearly evident in the included 
trials, a reason for the short duration from IVT-to-MT may be due to the delay in IVT 
administration in a trial setting, which involves recruitment, further imaging and 
randomisation processes, thereby distorting the real-world workflow. Moreover, in the 
included trials, all recruitment sites were MT-capable centres and hence the results only apply 
to patients presenting directly to such centres at a time when MT is immediately available.
Our sub-group analysis revealed that the two studies (DIRECT-MT and MR CLEAN NO-
IV), which included M2 occlusions, had higher successful reperfusion rates (TICI2b) in the 
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bridging therapy group than the remaining two studies that only included ICA and M1 MCA 
occlusions (Figure 4A). This may be due to the lower efficacy of IVT in proximal 
occlusions.25
There have been multiple previous systematic reviews and meta-analyses of predominantly 
observational studies comparing dMT and bridging therapy, which have yielded conflicting 
results.8,10 The most recent meta-analysis by Wang et al., which included 29 observational 
studies and one randomized trial (DIRECT-MT), concluded that better functional outcome 
(mRS≤2 at 90 days) was achieved with bridging therapy compared to dMT.10 However, there 
was an overlap of some patient cohorts in the included studies, and most of the observational 
studies were inherent to selection bias (particularly in the dMT cohort, many of whom were 
ineligible for IVT treatment). Reasons for IVT ineligibility include a delayed presentation 
from stroke onset, which predisposes to a larger ischaemic core, especially in patients with 
poor collateral circulation, as well as prior use of anticoagulants, both of which could affect 
haemorrhagic complications and functional outcomes. 
Furthermore, a subgroup analysis performed by Kaesmacher et al. of studies that only 
included patients eligible for IVT in the dMT cohort found no difference between both 
groups for the good functional outcome at 90 days, findings which are coherent with our 
analysis.26 Our findings are also difficult to directly compare with prior analyses that included 
observational studies of both anterior and posterior circulation strokes and first-generation SR 
devices27, which may have confounded the outcomes. Additionally, many retrospective 
studies did not report the outcomes of patients that received IVT but failed to proceed to MT 
due to clinical improvement and/or vessel reperfusion. All RCTs in our analysis used 
modern-day techniques and were deemed to have a low risk of bias and low heterogeneity. 
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Our analysis includes several limitations. First, the paucity of data on the outcomes according 
to the clot location, stroke aetiology (and correlating clot composition) or first-line MT 
techniques precluded sub-group analysis. Second, three of included studies were conducted in 
Asian populations, which limits generalizability of the findings to non-Asian populations. 
The remaining trials (SWIFT DIRECT and DIRECT SAFE) are expected to further inform 
this question. Third, there may be an inherent risk of bias in inclusion of the unpublished, 
non-peer-reviewed results from the MR CLEAN NO-IV study presented during the ISC 
2021. Fourth, all analyses were only performed on an intention-to-treat basis; thus the 
definitive treatment may be different from the group allocated, which may have influenced 
the results. Fifth, the studies only included patients with anterior circulation strokes, so they 
cannot be extended to all patients with ischemic stroke. Sixth, only alteplase was used for 
IVT, which precludes comparisons to potentially more effective or safer thrombolytics, such 
as tenecteplase.28 Finally, to fully understand the impact of treatment on clinical outcomes an 
ordinal shift mRS analysis should be performed on individual patient data.29
Conclusions
The combined trial data assessing dMT versus bridging therapy showed no difference in 
improving good functional outcome. The wide non-inferiority margins set by individual trials 
are in contrast with the clinical consensus on minimally important differences. However, our 
pooled analysis indicates non-inferiority of dMT with a 4% margin of confidence.  The 
application of these findings is limited to patients presenting directly to MT-capable centres 
and real-world workflow times may differ against those achieved in a trial setting. The results 
of further ongoing multi-centre randomized trials are awaited.
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Fig. 1. PRISMA flowchart of the study selection process
Fig. 2. Forest plot of primary clinical outcomes: good clinical outcome at 90 days (modified 
Rankin Score, mRS≤2). Lines at OR=0.74/0.8 indicate the reported non-inferiority margins in 
the included trials.
Fig. 3. Forest plots of secondary clinical outcomes A. excellent clinical outcome at 90 days 
(modified Rankin Score, mR≤1), B. mortality at 90 days, C. symptomatic intracranial 
haemorrhage (sICH), D. any ICH
Fig. 4. Forest plots of procedural outcomes A. successful reperfusion defined as TICI2b 
with a subgroup analysis stratified according to the study inclusion criteria of the clot 
localization. B. procedure-related complications.  ICA – internal carotid artery, M1 – M1 
segment of the middle cerebral artery, M2 - M2 segment of the middle cerebral artery
Fig. 5. Risk of bias. 
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 Author, year Zi, 2021 Yang, 2020 Roos, 2021 Suzuki, 2021 
Study design Non-inferiority Non-inferiority Superiority Non-inferiority
Allocation 
method
RCT RCT RCT RCT











Sample size – 
direct MT vs 
Bridging 
therapy





≤2) at 90 days
Ordinal mRS Ordinal mRS
Good clinical 
outcome (mRS 
≤2) at 90 days
Non-inferiority 
margin
-10% 0.8 0.8 0.74 










































MT-capable MT-capable MT-capable MT-capable
mRS≤2 at 90 
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Risk of bias Low Low Low Low
Tab. 1. Study characteristics
dMT – Direct mechanical thrombectomy, mRS – modified Rankin score, RCT – randomized 
controlled trial, TICI – thrombolysis in cerebral infarction, OR – Odds ratio. IQR – 
interquartile range, N/A not available 
* mean (SD), ** onset to alteplase, *** onset to groin, 
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Direct MT, n/N (%) or 
mean±SD/N
Bridging Therapy, n/N (%) 
or mean±SD/N
Socio-demographics
Sample size 817 816
Gender (male) 471/817 (57.6) 463/816 (56.7)





HTN 323/544 (59.4) 336/550 (61.1)
DM 100/544 (18.4) 102/550 (18.5)
Dyslipidaemia 48/544 (8.8) 59/550 (10.7)
AF 357/817 (43.7)  338/816 (41.4)
Prior Stroke 69/544 (12.7) 80/550 (14.5)
Prior CVD 37/544 (6.8) 26/550 (4.7)
Smoking 70/217 (32.3) 83/221 (37.6)
Medications
Antiplatelet 16/544 (2.9) 18/550 (3.3)
Anticoagulation 19/544 (3.5) 17/550 (3.1)
Clot Localization
ICA 239/817 (29.3) 216/816 (26.5)
M1 449/817 (54.6) 541/816 (66.3)
M2 90/817 (11.0) 75/816 (9.2)
Tandem occlusion 34/544 (6.3) 42/550 (7.6)
Stroke Etiology
Cardioembolic 278/544 (51.1) 285/550 (51.8)
Large Artery 
Atherosclerosis
87/544 (16) 72/550 (13.1)
Intracranial 
Atherosclerosis
54/443 (12.2) 42/447 (9.4)
Unknown/other 153/544 (28.1) 174/550 (31.6)
NIHSS=National Institutes of Health Stroke Scale, IV-tPA=intravenous tissue plasminogen 
activator, MT=mechanical thrombectomy, ASPECTS=Alberta stroke program early CT 
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score, HTN=hypertension, DM=diabetes mellitus, AF=atrial fibrillation, 
CVD=cardiovascular disease, ICA=internal carotid artery, M1=M1 segment of the middle 
cerebral artery, M2=M2 segment of the middle cerebral artery
Table 2: Baseline population characteristics 
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Fig. 1. PRISMA flowchart 
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Fig. 2. Forest plot of primary clinical outcomes: good clinical outcome at 90 days (modified 
Rankin Score, mRS≤2). Lines at OR=0.74/0.8 indicate the reported non-inferiority margins in 
the included trials.
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Fig. 3. Forest plots of secondary clinical outcomes A. excellent clinical outcome at 90 days 
(modified Rankin Score, mR≤1), B. mortality at 90 days, C. symptomatic intracranial 
haemorrhage (sICH), D. any ICH
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Fig. 4. Forest plots of procedural outcomes A. successful reperfusion defined as TICI2b 
with a subgroup analysis stratified according to the study inclusion criteria of the clot 
localization. B. procedure-related complications.   ICA=internal carotid artery, M1=M1 
segment of the middle cerebral artery, M2=M2 segment of the middle cerebral artery
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Fig. 5. Risk of bias
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